Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Puretech Health Plc (PRTC.LN)

Puretech Health Plc (PRTC.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Puretech Health Plc 6 Tide Street Suite 400 Boston MA 02210 USA

https://www.puretechhealth.com P: 617-482-2333 F: 617-482-3337

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Key Statistics

Overview:

Market Capitalization, $K 305,005
Shares Outstanding, K 241,684
Annual Sales, $ 4,315 K
Annual Net Income, $ 53,510 K
% of Insider Shareholders 13.44%
% of Institutional Shareholders 53.06%

Growth:

1-Year Return -18.48%
3-Year Return -52.65%
5-Year Return -68.45%
5-Year Revenue Growth -13.06%
5-Year Earnings Growth -31.96%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm 0.17
Dividend Payout Ratio 0.00%

PRTC.LN Ratios

Ratio
Price/Earnings ttm 10.03
Price/Earnings forward N/A
Return-on-Equity % 14.65%
Return-on-Assets % 8.94%
Profit Margin % 1,240.09%
Debt/Equity 0.04
Price/Sales 66.70
Price/Book 1.10
Book Value/Share 1.15
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar